GLP1R and heart failure: A meta-analysis of eight trials by Sattar et al. showed that the GLP-1 agonists were associated with reduced incidence of major adverse cardiovascular events (MACE) (HR 0.86; 95% CI 0.80-0.93) and hospital admission rates for heart failure (HR 0.89; 95% CI 0.82-0.98) [62].